Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.69 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.69 |
| ▸ | TNF | P01375 | 1/20 | 0.69 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL229982 | 0.90 | HTT (0.81) | HTTTDP1CYP11B1CYP11B2TNF | |
| SCHEMBL24041743 | 0.87 | HTT (0.76) | HTTTDP1CYP11B1CYP11B2TNF | |
| SCHEMBL16147345 | 0.87 | HTT (0.77) | HTTTDP1CYP11B1CYP11B2TNF | |
| SCHEMBL7259109 | 0.87 | HTT (0.77) | HTTTDP1CYP11B1CYP11B2TNF | |
| SCHEMBL13186931 | 0.87 | HTT (0.77) | HTTTDP1CYP11B1CYP11B2TNF | |
| SCHEMBL11313566 | 0.87 | HTT (0.77) | HTTTDP1CYP11B1CYP11B2TNF | |
| SCHEMBL24041805 | 0.86 | HTT (0.74) | HTTTDP1CYP11B1CYP11B2TNF | |
| Hydrochloric Acid SCHEMBL30341872 | 0.85 | HTT (0.74) | HTTTDP1CYP11B1CYP11B2TNF | |
| Hydrochloric Acid SCHEMBL29006871 | 0.85 | HTT (0.74) | HTTTDP1CYP11B1CYP11B2TNF | |
| SCHEMBL9775011 | 0.85 | HTT (0.74) | HTTTDP1CYP11B1CYP11B2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109020895-B | Synthesis method of metal-catalyzed 1-benzylamino-substituted benzimidazole | 枣庄学院 | 2020-04-24 | — | — | CN | claimed |
| EP-2080822-B1 | DIRECT PLATING METHOD AND SOLUTION FOR PALLADIUM CONDUCTOR LAYER FORMATION | UEMURA KOGYO KK (JP) | 2017-03-29 | — | — | EP | claimed |
| US-8992756-B2 | Direct plating method and solution for palladium conductor layer formation | C. UYEMURA & CO., LTD. (JP) | 2015-03-31 | — | — | US | claimed |
| US-20230018423-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | YODA THERAPEUTICS INC. (TW) | 2023-01-19 | — | — | US | disclosed |
| US-11370775-B2 | Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors | Tseng, Yufeng Jane (US) | 2022-06-28 | — | — | US | disclosed |
| CN-109020895-A | A kind of synthetic method of the 1- benzamido group substituted benzimidazole of metal catalytic | 枣庄学院 | 2018-12-18 | — | — | CN | disclosed |
| EP-2080822-B1 | DIRECT PLATING METHOD AND SOLUTION FOR PALLADIUM CONDUCTOR LAYER FORMATION | UEMURA KOGYO KK (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-8992756-B2 | Direct plating method and solution for palladium conductor layer formation | C. UYEMURA & CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8766437-B2 | Electrode structure, wiring body, adhesive connection structure, electronic device, and method for fabricating same | SUMITOMO ELECTRIC INDUSTRIES, LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-1401838-B1 | NOVEL SUBSTITUTED TETRACYCLIC IMIDAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE AS A MEDICINE | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-26 | — | — | EP | disclosed |
| EP-2440024-B1 | CONNECTION METHOD | SUMITOMO ELECTRIC INDUSTRIES (JP) | 2014-03-12 | — | — | EP | disclosed |
| EP-1829987-A2 | Surface treating agent and method for manufacturing coating using the same | MEC COMPANY LTD. (JP) | 2007-09-05 | — | — | EP | disclosed |
| EP-1451196-B1 | The use of substituted tetracyclic imidazole derivatives as anti-histaminics | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| CN-1895673-A | The use of substituted tetracyclic imidazole derivatives as anti-histaminics | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-17 | — | — | CN | disclosed |
| US-20050070525-A1 | Use of anti-histaminics for acute reduction of elevated intracranial pressure | JANSSEN-CILAG GMBH (DE) | 2005-03-31 | — | — | US | disclosed |
| EP-1451196-A1 | THE USE OF ANTI-HISTAMINICS FOR ACUTE REDUCTION OF ELEVATED INTRACRANIAL PRESSURE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-01 | — | — | EP | disclosed |
| US-20040167138-A1 | Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharamaceutical compositions comprising them and their use as a medicine | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-26 | — | — | US | disclosed |
| EP-1401838-A2 | NOVEL SUBSTITUTED TETRACYCLIC IMIDAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003044023-A1 | THE USE OF ANTI-HISTAMINICS FOR ACUTE REDUCTION OF ELEVATED INTRACRANIAL PRESSURE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-30 | — | — | WO | disclosed |
| WO-2002100862-A2 | NOVEL SUBSTITUTED TETRACYCLIC IMIDAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070525-A1 | Use of anti-histaminics for acute reduction of elevated intracranial pressure | HRH2, HRH3, HRH4 | HTT 2674/4885TDP1 3571/4885CYP11B1 1538/4885 |
| US-20230018423-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | NLRP3, NOD1, NLRP1 | HTT 2343/4885TDP1 343/4885CYP11B1 74/4885 |
| US-11370775-B2 | Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors | DAO, DDO, IL4I1 | HTT 3592/4885TDP1 1108/4885CYP11B1 633/4885 |
| US-20040167138-A1 | Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharamaceutical compositions comprising them and their use as a medicine | AIFM1, PTGIS, ATP6V1B2 | HTT 4117/4885TDP1 1616/4885CYP11B1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.